{
    "_links": {
        "self": {
            "href": "http:\/\/localhost:8080\/article\/one-year-after-proposition-71-shape-ca-stem-cell-program-still-uncertain?_format=hal_json"
        },
        "type": {
            "href": "http:\/\/drupal.org\/rest\/type\/node\/article"
        },
        "http:\/\/drupal.org\/rest\/relation\/node\/article\/revision_uid": [
            {
                "href": "http:\/\/localhost:8080\/user\/2?_format=hal_json"
            }
        ],
        "http:\/\/drupal.org\/rest\/relation\/node\/article\/uid": [
            {
                "href": "http:\/\/localhost:8080\/user\/2?_format=hal_json",
                "lang": "en"
            }
        ]
    },
    "nid": [
        {
            "value": 203
        }
    ],
    "uuid": [
        {
            "value": "f76c5b97-94f3-4a93-9742-60f19d75f33b"
        }
    ],
    "vid": [
        {
            "value": 203
        }
    ],
    "langcode": [
        {
            "value": "en",
            "lang": "en"
        }
    ],
    "type": [
        {
            "target_id": "article"
        }
    ],
    "revision_timestamp": [
        {
            "value": "2020-02-13T07:45:06+00:00",
            "format": "Y-m-d\\TH:i:sP"
        }
    ],
    "_embedded": {
        "http:\/\/drupal.org\/rest\/relation\/node\/article\/revision_uid": [
            {
                "_links": {
                    "self": {
                        "href": "http:\/\/localhost:8080\/user\/2?_format=hal_json"
                    },
                    "type": {
                        "href": "http:\/\/drupal.org\/rest\/type\/user\/user"
                    }
                },
                "uuid": [
                    {
                        "value": "20b60d4b-bf21-4da9-8d41-4af6bd4e47ba"
                    }
                ]
            }
        ],
        "http:\/\/drupal.org\/rest\/relation\/node\/article\/uid": [
            {
                "_links": {
                    "self": {
                        "href": "http:\/\/localhost:8080\/user\/2?_format=hal_json"
                    },
                    "type": {
                        "href": "http:\/\/drupal.org\/rest\/type\/user\/user"
                    }
                },
                "uuid": [
                    {
                        "value": "20b60d4b-bf21-4da9-8d41-4af6bd4e47ba"
                    }
                ],
                "lang": "en"
            }
        ]
    },
    "status": [
        {
            "value": true,
            "lang": "en"
        }
    ],
    "title": [
        {
            "value": "One year after Proposition 71: Shape of CA Stem Cell Program Still Uncertain",
            "lang": "en"
        }
    ],
    "created": [
        {
            "value": "2014-04-01T16:59:45+00:00",
            "lang": "en",
            "format": "Y-m-d\\TH:i:sP"
        }
    ],
    "changed": [
        {
            "value": "2019-04-09T21:02:16+00:00",
            "lang": "en",
            "format": "Y-m-d\\TH:i:sP"
        }
    ],
    "promote": [
        {
            "value": false,
            "lang": "en"
        }
    ],
    "sticky": [
        {
            "value": false,
            "lang": "en"
        }
    ],
    "default_langcode": [
        {
            "value": true,
            "lang": "en"
        }
    ],
    "revision_translation_affected": [
        {
            "value": true,
            "lang": "en"
        }
    ],
    "metatag": [
        {
            "value": []
        }
    ],
    "path": [
        {
            "alias": "\/article\/one-year-after-proposition-71-shape-ca-stem-cell-program-still-uncertain",
            "pid": 256,
            "langcode": "en",
            "lang": "en"
        }
    ],
    "value": "Washington, D.C. - Nearly one year after California declared independence from the federal government\u2032s restrictions on funding embryonic stem cell research, FasterCures has released a case study that analyzes the reality created by the initiative and concludes it is too soon to tell whether the state\u2032s effort is the right way, or even a good way, to support research the federal government will not. \"California\u2032s bold stroke to pursue stem cell research free from federal restrictions - and federal dollars - has been slowed by the debate over how to assemble a governing structure for the new Institute,\" said FasterCures President Greg Simon. \"They\u2032ve come a long way. But the real question is whether they can quickly resolve these debates in a way that allows them to fund the kind of high risk, high reward research that the public expects in order to make progress in the fight against disease.\" When California voters approved the initiative 59-41 percent on November 2, 2004, it marked the first time state taxpayers have directly funded specific scientific research in order to compensate for federal restrictions. The $3 billion bond measure established the California Institute for Regenerative Medicine (CIRM) to regulate and provide funding for stem cell research. In the year since the ballot measure passed, many other states have also moved to support embryonic stem cell research. FasterCures' report, \"Proposition 71: A Model for State Involvement in Biomedical Research?\" examines the challenges other states might face as they consider similar or related investments in embryonic stem cell research or other areas of research not supported by the federal government for ideological or political reasons. The case study: reviews the controversies of over 30 years of federal embryo research policy; <b> describes the passage of Proposition 71; <br> catalogues states\u2032 efforts to support embryonic stem cell research as an economic development tool; <br> examines the post-election challenges to CIRM in the legislature and the courts; <br> details the difficult issues CIRM faces, including: - oversight; <br>\n- conflicts of interest; <br>\n- peer review, openness, and transparency; <br>\n- intellectual property issues; and, <br>- access to care by low-income Californians. Lessons learned: Passing Proposition 71 did not insulate embryonic stem cell research from political risk; it faces challenges from the Legislature and in court. <br> The mere endorsement of this research, before any money has been handed out, has catalyzed an intensive redirection of talent and resources, both inside the state and out. <br> There are dangers in overselling the potential benefits - both in the form of cures and in intellectual property revenues - of such an investment. <br> There are advantages and disadvantages to creating a new research infrastructure from the ground up, rather than using existing infrastructure and institutions. <br> As emerging technologies create conflict and controversy, states may be much better situated to take charge than the federal government. <br> CIRM is adopting - in many cases, being forced to adopt - the traditional approach to funding used by NIH. It does not appear to feel the need to experiment with entirely new funding or disbursement models. <br> The California initiative has provided an opportunity to move faster, if not quickly, in a controversial area of research. <br> While there has been much focus on the administration of CIRM, the true measure of whether Proposition 71 has been a success will be in the science and therapies that result from California\u2032s investment. The report is available on FasterCures' website at www.fastercures.org. <b>Contact at FasterCures: <\/b><br>\nCatherine Berger<br>(202) 654-7085<br>cberger@fastercures.org About FasterCures:<br>\nFasterCures \/ The Center for Accelerating Medical Solutions is committed to accelerating the medical research process to find new treatments for deadly and debilitating diseases. FasterCures was founded by Mike Milken as an initiative of the Milken Institute and is nonpartisan, nonprofit and independent of interest groups. The board of directors includes Mike Milken, Nobel laureates David Baltimore and Gary Becker and Nancy Brinker, founder of the Susan G. Komen Breast Cancer Foundation. For more information, visit www.fastercures.org.",
    "format": "rich_text",
    "processed": "Washington, D.C. - Nearly one year after California declared independence from the federal government\u2032s restrictions on funding embryonic stem cell research, FasterCures has released a case study that analyzes the reality created by the initiative and concludes it is too soon to tell whether the state\u2032s effort is the right way, or even a good way, to support research the federal government will not. \"California\u2032s bold stroke to pursue stem cell research free from federal restrictions - and federal dollars - has been slowed by the debate over how to assemble a governing structure for the new Institute,\" said FasterCures President Greg Simon. \"They\u2032ve come a long way. But the real question is whether they can quickly resolve these debates in a way that allows them to fund the kind of high risk, high reward research that the public expects in order to make progress in the fight against disease.\" When California voters approved the initiative 59-41 percent on November 2, 2004, it marked the first time state taxpayers have directly funded specific scientific research in order to compensate for federal restrictions. The $3 billion bond measure established the California Institute for Regenerative Medicine (CIRM) to regulate and provide funding for stem cell research. In the year since the ballot measure passed, many other states have also moved to support embryonic stem cell research. FasterCures' report, \"Proposition 71: A Model for State Involvement in Biomedical Research?\" examines the challenges other states might face as they consider similar or related investments in embryonic stem cell research or other areas of research not supported by the federal government for ideological or political reasons. The case study: reviews the controversies of over 30 years of federal embryo research policy; <b> describes the passage of Proposition 71; <br \/> catalogues states\u2032 efforts to support embryonic stem cell research as an economic development tool; <br \/> examines the post-election challenges to CIRM in the legislature and the courts; <br \/> details the difficult issues CIRM faces, including: - oversight; <br \/>\n- conflicts of interest; <br \/>\n- peer review, openness, and transparency; <br \/>\n- intellectual property issues; and, <br \/>- access to care by low-income Californians. Lessons learned: Passing Proposition 71 did not insulate embryonic stem cell research from political risk; it faces challenges from the Legislature and in court. <br \/> The mere endorsement of this research, before any money has been handed out, has catalyzed an intensive redirection of talent and resources, both inside the state and out. <br \/> There are dangers in overselling the potential benefits - both in the form of cures and in intellectual property revenues - of such an investment. <br \/> There are advantages and disadvantages to creating a new research infrastructure from the ground up, rather than using existing infrastructure and institutions. <br \/> As emerging technologies create conflict and controversy, states may be much better situated to take charge than the federal government. <br \/> CIRM is adopting - in many cases, being forced to adopt - the traditional approach to funding used by NIH. It does not appear to feel the need to experiment with entirely new funding or disbursement models. <br \/> The California initiative has provided an opportunity to move faster, if not quickly, in a controversial area of research. <br \/> While there has been much focus on the administration of CIRM, the true measure of whether Proposition 71 has been a success will be in the science and therapies that result from California\u2032s investment. The report is available on FasterCures' website at www.fastercures.org. <b>Contact at FasterCures: <\/b><br \/>\nCatherine Berger<br \/>(202) 654-7085<br \/>cberger@fastercures.org About FasterCures:<br \/>\nFasterCures \/ The Center for Accelerating Medical Solutions is committed to accelerating the medical research process to find new treatments for deadly and debilitating diseases. FasterCures was founded by Mike Milken as an initiative of the Milken Institute and is nonpartisan, nonprofit and independent of interest groups. The board of directors includes Mike Milken, Nobel laureates David Baltimore and Gary Becker and Nancy Brinker, founder of the Susan G. Komen Breast Cancer Foundation. For more information, visit www.fastercures.org.<\/b>",
    "summary": null,
    "summary_processed": ""
}